Grom / Thornton Lab

Publications

Maccora, I; Brunner, HI; Cassedy, A; Altaye, M; Quinlan-Waters, M; Lovell, DJ; Grom, A; Angeles-Han, ST. Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 2025; 7:e11751.

Baldo, F; Erkens, RG A; Mizuta, M; Rogani, G; Lucioni, F; Bracaglia, C; Foell, D; Gattorno, M; Jelusic, M; Anton, J; Ruperto, N; Swart, JF; Vastert, S; Minoia, F. Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology. 2025; 64:32-44.

Brunner, HI; Schulert, GS; Sproles, A; Thornton, S; Cornejo, GV; Antón, J; Cuttica, R; Henrickson, M; Foeldvari, I; Kingsbury, DJ; Lovell, DJ; Martini, A; Ruperto, N; Grom, AA. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.

Ogbu, EA; Brunner, HI; Eloseily, E; Aviel, YB; Nanda, K; Schmeling, H; Tory, H; Uziel, Y; Viola, DO; Wahezi, DM; Ruperto, N; Huang, B; Grom, A; Thornton, S. Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1723-1732.

Fautrel, B; Mitrovic, S; De Matteis, A; Bindoli, S; Antón, J; Belot, A; Bracaglia, C; Constantin, T; Dagna, L; Di Bartolo, A; Wilhelmer, T; Wouters, C; Carmona, L; De Benedetti, F. EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Annals of the Rheumatic Diseases. 2024; 83:1614-1627.

Correia Marques, M; Rubin, D; Shuldiner, EG; Datta, M; Schmitz, E; Gutierrez Cruz, G; Patt, A; Bennett, E; Grom, A; Foell, D; Woo, P; Yeung, RS M; Zeft, AS; Zeggini, E. Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2024; 76:1566-1572.

Lovell, DJ; Tzaribachev, N; Henrickson, M; Simonini, G; Griffin, TA; Alexeeva, E; Bohnsack, JF; Zeft, A; Horneff, G; Vehe, RK; Costanzo, D; Rennebohm, R; Waugaman, B; Brodus, E. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.

Huang, Y; Sompii-Montgomery, L; Patti, J; Pickering, A; Yasin, S; Do, T; Baker, E; Gao, D; Abdul-Aziz, R; Behrens, EM; Ting, T; Grom, AA; Towe, C; Schulert, GS. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76:328-339.

Peng, J; Dönnes, P; Ardoin, SP; Schanberg, LE; Lewandowski, L; Ardoin, S; Dewitt, EM; Rabinovich, CE; Ellis, J; Mieszkalski, K; Paepke-Tollefsrud, DE; Robinson, G; Jury, EC; Ciurtin, C. Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis and Rheumatology. 2024; 76:455-468.

Vega-Fernandez, P; Rogers, K; Sproles, A; Thornton, S; Huggins, J; Lovell, DJ; Cassedy, A; Meyers, AB; Ting, TV. Diagnostic Accuracy Study of the Pediatric-Specific Ultrasound Scoring System for the Knee Joint in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:251-258.

Sinha, R; De Benedetti, F; Grom, AA; participants listed below, . Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022. Pediatric Rheumatology Online Journal. 2024; 21:91.

Schulert, G; Vastert, SJ; Grom, AA. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.

Grom, AA; Canna, SW; Abu-Arja, RF; Sinha, R; Peixoto, L; Cannizzaro, E; Chandrakasan, S; Driest, K; Marsh, R; Neven, B; Schulert, G; Silva, JM F; Wall, D; Zeilhofer, U. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.

de Benedetti, F; Grom, AA; Brunner, H. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.

Grom, AA. Genetics of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Advances in Experimental Medicine and Biology. 2024; 1448:121-126.

Erkens, RG A; Calis, JJ A; Verwoerd, A; De Roock, S; Ter Haar, NM; Den Engelsman, G; Van der Veken, LT; Ernst, RF; Van Deutekom, HW M; Pickering, A; Schulert, GS; Grom, AA; Van Loosdregt, J; Vastert, SJ. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.

Verweyen, EL; Thakkar, K; Dhakal, S; Baker, E; Chetal, K; Schnell, D; Canna, S; Grom, AA; Salomonis, N; Schulert, GS. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133:e166741.

Towe, C; Grom, AA; Schulert, GS. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; de Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; De Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.

De Benedetti, F; Grom, A; Brogan, P; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, G; Quartier, P; Asnaghi, V; Ballabio, M; Jacqmin, P; De Min, C. OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). Annals of the Rheumatic Diseases. 2023; 82:110-111.

De Benedetti, F; Grom, AA; Brogan, PA; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, GS; Quartier, P; Asnaghi, V; Ballabio, M; Jacqmin, P; De Min, C. Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.

Vega-Fernandez, P; Ting, TV; Mar, DA; Schapiro, AH; Deluna, MD; Saper, VE; Grom, AA; Schulert, GS; Fairchild, RM. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75:983-988.

Chimote, AA; Mayhew, C; Thornton, S; Wetzel, C; White, AN. Implementing Research Shared (Core) Facility Billing Systems. Journal of biomolecular techniques : JBT. 2022; 33:3fc1f5fe.1a877626.

Miraldi Utz, V; Angeles-Han, ST; Mwase, N; Cassedy, A; Hennard, T; Lovell, DJ; Lopper, S; Brunner, HI; Dosunmu, EO; Grom, AA; Henrickson, M; Huggins, JL; Sisk, RA; Ting, TV; Kaufman, AH. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.

Chen, G; Deutsch, GH; Schulert, GS; Zheng, H; Jang, SR; Trapnell, B; Lee, PY; Macaubas, C; Ho, K; Schneider, C; Goldbach-Mansky, R; Khatri, P; Mellins, ED; Canna, SW. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.

Back, JB; Martinez, L; Nettenstrom, L; Sheerar, D; Thornton, S. Establishing a biosafety plan for a flow cytometry shared resource laboratory. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2022; 101:380-386.

Chalhoub, NE; Wenderfer, SE; Levy, DM; Rouster-Stevens, K; Aggarwal, A; Savani, SI; Ruth, NM; Arkachaisri, T; Qiu, T; Merritt, A; Hoffmann, S; Hollander, M; Hom, C; Houk, L. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.

Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; Altaye, M; Holland, GN. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.

De Benedetti, F; Prencipe, G; Bracaglia, C; Marasco, E; Grom, AA. Targeting interferon-γ in hyperinflammation: opportunities and challenges. Nature reviews. Rheumatology. 2021; 17:678-691.

Gao, DK; Salomonis, N; Henderlight, M; Woods, C; Thakkar, K; Grom, AA; Thornton, S; Jordan, MB; Wikenheiser-Brokamp, KA; Schulert, GS. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. JCI insight. 2021; 6:e147593.

Kessel, C; Fall, N; Grom, A; de Jager, W; Vastert, S; Strippoli, R; Bracaglia, C; Sundberg, E; Horne, AC; Ehl, S; Kessel, K; Beutel, K; Foell, D; Holzinger, D. Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. The Lancet. Rheumatology. 2021; 3:e563-e573.

Rodriguez-Smith, JJ; Verweyen, EL; Clay, GM; Esteban, YM; de Loizaga, SR; Baker, EJ; Do, T; Dhakal, S; Lang, SM; Grom, AA; Grier, D; Schulert, GS. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet. Rheumatology. 2021; 3:e574-e584.

Verweyen, EL; Pickering, A; Grom, AA; Schulert, GS. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2021; 73:1334-1340.

Cheung, P; Schaffert, S; Chang, SE; Dvorak, M; Donato, M; Macaubas, C; Foecke, MH; Li, TM; Zhang, L; Coan, JP; Mellins, ED; Khatri, P; Utz, PJ; Kuo, AJ. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nature Immunology. 2021; 22:711-722.

Luo, S; Clarke, SL N; Ramanan, AV; Thompson, SD; Langefeld, CD; Marion, MC; Grom, AA; Schooling, CM; Gaunt, TR; Yeung, SL A; Zheng, J. Platelet Glycoprotein Ib α-Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study. Arthritis and Rheumatology. 2021; 73:693-701.

Kim, H; Dill, S; O'Brien, M; Vian, L; Li, X; Manukyan, M; Jain, M; Adeojo, LW; George, J; Perez, M; Tsai, WL; Gadina, M; Rider, LG; Colbert, RA. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the Rheumatic Diseases. 2021; 80:406-408.

Daniels, K; Conway, A; Gardner, R; Martinez, L; Price, KM; Schneider, S; Sheridan, R; Srivastava, J; Thornton, S. Remote Training of SRL Users and Staff in a Global Pandemic. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2021; 99:42-50.

Aspland, AM; Douagi, I; Filby, A; Jellison, ER; Martinez, L; Shinko, D; Smith, AL; Tang, VA; Thornton, S. Biosafety during a pandemic: shared resource laboratories rise to the challenge. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2021; 99:68-80.